Why GlaxoSmithKline plc Beats AstraZeneca plc And Royal Dutch Shell Plc Beats BP plc For Your Last-Minute ISA

Pharma and oil are great sectors but GlaxoSmithKline plc (LON:GSK) and Royal Dutch Shell Plc (LON:RDSB) are better than AstraZeneca plc (LON:AZN) and BP plc (LON:BP)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceuticals and Big Oil are great sectors for the kind of long-term investment that ISAs are perfect for. It’s generally better to put the tax-wrapper of an ISA around funds that you plan to leave to grow the longest.

Pharma is a good sector because it is both defensive and a play on demographics in the West and East. Fierce opposition to any threatened cuts in the NHS budget demonstrate how protective people are of health services even in times of austerity. A good slug of the money that flows into healthcare ends up in the coffers of the drug companies — in bad times as in good. That’s what makes a defensive investment.

Demand for drugs will rise and rise. In the West the baby-boomers have become the grey vote, living longer and demanding new treatments to keep them healthy in old age. In emerging markets the rise of a wealthier and more-demanding middle class will fuel spending on healthcare.

The oil sector is out of favour after the precipitous plummet in oil prices. That, for me, is precisely the reason to invest in it now. “I bought Shell (LSE: RDSB) (NYSE: RDS-B.US) when oil was $50″ might not prove to be as big a boast as “I bought Microsoft/Amazon/Google for $1″, but then it’s not such a big risk either. There’s a good chance of mean-reversion, i.e. the operation of market forces, pushing up oil prices eventually. But in any event Big Oil will adapt to the market conditions that prevail over its long-term planning horizons.

Top-down

If you adopt that top-down approach to investing, then the LSE gives you a choice of two big players in each sector. Diversification is a great thing so it can make sense to ride both horses – but for my money there’s a clear winner in each industry.

GlaxoSmithKline (LSE: GSK) has a robust business model, with lower-risk consumer healthcare and vaccines adding ballast to its patent drugs business. GSK’s scale is a big competitive advantage, enabling it to spend heavily on R&D as well as giving it marketing fire-power. The company’s investment in emerging markets should also pay off long-term, despite high-profile stumbles in China.

CEO Pascal Soriot has focused AstraZeneca (LSE: AZN) totally on R&D-led pharma. The company became a biotech play with a dividend attached. Then along came Pfizer’s bid and the share price rocketed. Astra has made significant progress in both its pipeline and its P&L, but the shares have been kept at lofty heights by management’s big promises. My fear is that any disappointment would see the stock punished along with management.

Dividends

Shell has been paying an ever-increasing dividend since 1945, so the 50% drop in oil prices over the past eight months is just a blip in its history. CEO Ben van Beurden has been cutting costs and capital expenditure, a process that could be accelerated if necessary to maintain the cash flow and payout. The US administration is poised to allow Shell to resume drilling in the Alaskan Arctic, which should augur well for its future reserves.

Meanwhile BP (LSE: BP) is still counting the cost of its oil spill in the Gulf of Mexico. The uncertainty of just how many billions of dollars in fines and compensation it will ultimately pay hangs over the company’s valuation. BP is also extraordinarily exposed to Russia: its 20% share in state-owned Rosneft accounts for over half its proven reserves of oil and nearly a quarter of its gas. That’s a double-whammy of risk. BP has a track record of being done over (Sidanko) and having close scrapes (TNK-BP) in Russia. Western sanctions now place the company between a rock and a hard place.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony Reading owns shares in GlaxoSmithKline and Shell. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At a 20-year low, could this FTSE 250 stock be a value investor’s dream?

Scouring the FTSE 250 for bargains, Andrew Mackie has his eyes on this consumer goods multinational that has fallen on…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 discounted US stock for me to buy for the cybersecurity revolution!

This AI-powered cybersecurity company's beating its rival technologies, and a recent share price drop may have just created a buying…

Read more »

Investing Articles

Buying 1,019 shares of this FTSE 100 monopoly could earn me £2,284 in passive income

National Grid’s monopoly status makes it a popular passive income stock. But investors shouldn’t underestimate the risks that come with…

Read more »

Investing Articles

£5k in savings? Here’s how I’d aim to build a rising passive income of £5,500 a month

Harvey Jones invests in FTSE 100 dividend stocks with the aim of generating a growing passive income to fund his…

Read more »

Investing Articles

Are these 2 legendary dividend stocks worth buying and holding until 2030?

Zaven Boyrazian explores two of the UK's most legendary dividend stocks with tremendous track records. But are they good long-term…

Read more »

Investing Articles

I’d listen to Warren Buffett’s advice and buy undervalued shares today

Warren Buffett’s focus on quality at a reasonable price has proven to be a highly lucrative strategy that other investors…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

How I’d aim to turn an empty ISA into a £50k second income!

Zaven Boyrazian outlines how investors can target a £50,000 second income starting with a brand new ISA while also keeping…

Read more »

Investing Articles

Up 202%! This hidden FTSE gem has outpaced the Rolls-Royce share price and is still climbing!

The Rolls-Royce share price may have outpaced every FTSE 100 rival over the last couple of years but Harvey Jones…

Read more »